Kayne Anderson Rudnick Investment Management LLC Has $19.66 Million Stake in STERIS plc (NYSE:STE)

Kayne Anderson Rudnick Investment Management LLC grew its position in STERIS plc (NYSE:STE - Free Report) by 8.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 95,615 shares of the medical equipment provider's stock after purchasing an additional 7,285 shares during the period. Kayne Anderson Rudnick Investment Management LLC owned approximately 0.10% of STERIS worth $19,655,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Avalon Trust Co acquired a new position in shares of STERIS during the fourth quarter worth approximately $30,000. Human Investing LLC bought a new stake in STERIS during the 4th quarter valued at $31,000. Anfield Capital Management LLC boosted its position in STERIS by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock worth $37,000 after acquiring an additional 91 shares during the period. Central Pacific Bank Trust Division grew its stake in shares of STERIS by 65.5% in the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 76 shares in the last quarter. Finally, Manchester Capital Management LLC grew its stake in shares of STERIS by 182.7% in the fourth quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock worth $44,000 after purchasing an additional 137 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on STE. Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a report on Monday, April 7th. Piper Sandler upped their price target on shares of STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. JMP Securities reiterated a "market outperform" rating and set a $265.00 price objective on shares of STERIS in a research note on Thursday, April 10th. Finally, Stephens reissued an "overweight" rating and set a $240.00 target price on shares of STERIS in a report on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $258.75.

STERIS Price Performance

Shares of STE traded down $1.35 during trading hours on Friday, hitting $225.00. 368,819 shares of the company were exchanged, compared to its average volume of 525,239. The firm has a fifty day simple moving average of $222.89 and a 200-day simple moving average of $218.95. The company has a market capitalization of $22.11 billion, a PE ratio of 47.77 and a beta of 0.87. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.13 and a quick ratio of 1.40. STERIS plc has a one year low of $200.45 and a one year high of $248.24.

STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. As a group, sell-side analysts predict that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 21st. Shareholders of record on Thursday, February 20th were given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 1.01%. The ex-dividend date of this dividend was Thursday, February 20th. STERIS's payout ratio is 48.41%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.